190 related articles for article (PubMed ID: 21921645)
21. Iron Supplementation for Chemotherapy-Induced Anemia in Patients Receiving Erythropoiesis-Stimulating Agents.
Mhaskar R; Djulbegovic B
JAMA Oncol; 2016 Nov; 2(11):1499-1500. PubMed ID: 27387766
[TBL] [Abstract][Full Text] [Related]
22. Continued challenges with the use of erythropoiesis-stimulating agents in patients with cancer: perspectives and issues on policy-guided health care.
Arbuckle RB; Griffith NL; Iacovelli LM; Johnson PE; Jorgenson JA; Kloth DD; Lucarelli CD; Muller RJ
Pharmacotherapy; 2008 May; 28(5 Pt 2):1S-15S. PubMed ID: 18447704
[TBL] [Abstract][Full Text] [Related]
23. Parenteral iron with erythropoiesis-stimulating agents for chemotherapy-induced anemia.
Shord SS; Hamilton JM; Cuellar S
J Oncol Pharm Pract; 2008 Mar; 14(1):5-22. PubMed ID: 18337436
[TBL] [Abstract][Full Text] [Related]
24. It's time to compare anemia management strategies in hemodialysis.
Coyne DW
Clin J Am Soc Nephrol; 2010 Apr; 5(4):740-2. PubMed ID: 20299363
[TBL] [Abstract][Full Text] [Related]
25. Management of anemia in advanced breast and lung cancer patients in daily practice: results of a French survey.
Ray-Coquard I; Morère JF; Scotté F; Cals L; Antoine EC
Adv Ther; 2012 Feb; 29(2):124-33. PubMed ID: 22314432
[TBL] [Abstract][Full Text] [Related]
26. Twist and shout: one decade of meta-analyses of erythropoiesis-stimulating agents in cancer patients.
Bohlius J; Tonia T; Schwarzer G
Acta Haematol; 2011; 125(1-2):55-67. PubMed ID: 21150188
[TBL] [Abstract][Full Text] [Related]
27. Cost savings from anemia management with biosimilar epoetin alfa and increased access to targeted antineoplastic treatment: a simulation for the EU G5 countries.
Abraham I; Han L; Sun D; MacDonald K; Aapro M
Future Oncol; 2014; 10(9):1599-609. PubMed ID: 25145430
[TBL] [Abstract][Full Text] [Related]
28. Erythropoietin in cancer patients.
Glaspy JA
Annu Rev Med; 2009; 60():181-92. PubMed ID: 18980468
[TBL] [Abstract][Full Text] [Related]
29. Impact of limiting erythropoiesis-stimulating agent use for chemotherapy-induced anemia on the United States blood supply margin.
Vekeman F; Bookhart BK; White J; McKenzie RS; Duh MS; Piech CT; Lefebvre P
Transfusion; 2009 May; 49(5):895-902. PubMed ID: 19175548
[TBL] [Abstract][Full Text] [Related]
30. Costs of managing anemia with erythropoiesis-stimulating agents during hemodialysis: a time and motion study.
Schiller B; Doss S; DE Cock E; Del Aguila MA; Nissenson AR
Hemodial Int; 2008 Oct; 12(4):441-9. PubMed ID: 19090867
[TBL] [Abstract][Full Text] [Related]
31. Impact of Centers for Medicare & Medicaid Services national coverage determination on erythropoiesis-stimulating agent and transfusion use in chemotherapy-treated cancer patients.
Arneson TJ; Li S; Gilbertson DT; Bridges KR; Acquavella JF; Collins AJ
Pharmacoepidemiol Drug Saf; 2012 Aug; 21(8):857-64. PubMed ID: 22450901
[TBL] [Abstract][Full Text] [Related]
32. Cost analysis: treatment of chemotherapy-induced anemia with erythropoiesis-stimulating agents in five European countries.
Duran A; Spaepen E; Lamotte M; Walter E; Umuhire D; Lucioni C; Pinheiro B; Brosa M; Kutikova L; Pujol B; Van Belle S; Annemans L
J Med Econ; 2012; 15(3):409-18. PubMed ID: 22208527
[TBL] [Abstract][Full Text] [Related]
33. Management of anemia in cancer patients.
Calabrich A; Katz A
Future Oncol; 2011 Apr; 7(4):507-17. PubMed ID: 21463140
[TBL] [Abstract][Full Text] [Related]
34. Effect of reimbursement changes on erythropoiesis-stimulating agent utilization and transfusions.
Hess G; Nordyke RJ; Hill J; Hulnick S
Am J Hematol; 2010 Nov; 85(11):838-43. PubMed ID: 20976794
[TBL] [Abstract][Full Text] [Related]
35. The influence of need-based, continuous, low-dose iron replacement on hemoglobin levels in hemodialysis patients treated with erythropoiesis-stimulating agents.
Malovrh M; Hojs N; Premru V
Artif Organs; 2011 Jan; 35(1):63-8. PubMed ID: 20618233
[TBL] [Abstract][Full Text] [Related]
36. Addition of iron to erythropoiesis-stimulating agents in cancer patients: a meta-analysis of randomized trials.
Petrelli F; Borgonovo K; Cabiddu M; Lonati V; Barni S
J Cancer Res Clin Oncol; 2012 Feb; 138(2):179-87. PubMed ID: 21972052
[TBL] [Abstract][Full Text] [Related]
37. Safety update on erythropoiesis-stimulating agents: trials within and outside the accepted indications.
Gascón P
Oncologist; 2008; 13 Suppl 3():4-10. PubMed ID: 18458118
[TBL] [Abstract][Full Text] [Related]
38. Cost-utility analysis of recombinant human erythropoietin in anemic cancer patients induced by chemotherapy in Thailand.
Roungrong J; Teerawattananon Y; Chaikledkaew U
J Med Assoc Thai; 2008 Jun; 91 Suppl 2():S119-25. PubMed ID: 19255987
[TBL] [Abstract][Full Text] [Related]
39. Bundled-rate legislation for Medicare reimbursement for dialysis services: implications for anemia management with ESAs.
Charytan C
Clin J Am Soc Nephrol; 2010 Dec; 5(12):2355-62. PubMed ID: 21071515
[TBL] [Abstract][Full Text] [Related]
40. A comprehensive vision for intravenous iron therapy.
Coyne DW
Am J Kidney Dis; 2008 Dec; 52(6 Suppl):S14-20. PubMed ID: 19010257
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
